Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Finished

EmboSure Disruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery

Coordinator
Crannmed Ltd, Ireland
Runs
1 May 2022 to 30 November 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190167448

What the project is doing

In the project's own words, from its summary on CORDIS.

EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed. The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period.

This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body. The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee. As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.

Who is involved

OrganisationCityCountryRole
Crannmed LtdGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI